We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: circulating tumor DNA
MedXY News
EnglishTag

circulating tumor DNA

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Optimizing Monitoring in Head and Neck Squamous Cell Carcinoma: Tissue-Informed ctDNA Assay Shows High Accuracy and Feasibility
newsXét nghiệm sinh thiết lỏngtissue-informed assay

Optimizing Monitoring in Head and Neck Squamous Cell Carcinoma: Tissue-Informed ctDNA Assay Shows High Accuracy and Feasibility

By MedXY|Sep 7, 2026

Tissue-informed circulating tumor DNA assays demonstrate high detection rates and exceptional sensitivity and specificity in monitoring HPV-positive and HPV-negative head and neck squamous cell carcinoma, supporting their clinical utility i

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay
Hematology-Oncology
measurable residual disease
Large B-Cell Lymphoma

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

By MedXY|Aug 25, 2026

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay fo

Advancing Early Triple Negative Breast Cancer Care: Tissue-Free Circulating Tumor DNA Assays for Molecular Residual Disease Detection
newsmolecular residual diseasetissue-free assay

Advancing Early Triple Negative Breast Cancer Care: Tissue-Free Circulating Tumor DNA Assays for Molecular Residual Disease Detection

By MedXY|Aug 17, 2026

A recent study comparing tissue-free and tumor-informed ctDNA assays in early triple negative breast cancer reveals comparable accuracy and earlier detection of molecular residual disease, supporting tissue-free approaches for routine clini

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
Gastroenterologyadjuvant chemotherapycirculating tumor DNA

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

By MedXY|Jul 4, 2026

This study reveals that circulating tumor DNA (ctDNA) status after colorectal liver metastasis surgery predicts survival outcomes and benefits from adjuvant chemotherapy, guiding personalized treatment.

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial
newscirculating tumor DNActDNA

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

By MedXY|Jun 28, 2026

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring sho

Circulating Tumor DNA-Guided Adjuvant Therapy: Recent Advances and Clinical Implications (2021–2025)
Clinical Updatesadjuvant therapycirculating tumor DNA

Circulating Tumor DNA-Guided Adjuvant Therapy: Recent Advances and Clinical Implications (2021–2025)

By MedXY|Nov 13, 2025

This review synthesizes recent evidence (2021–2025) on circulating tumor DNA-guided adjuvant therapy, highlighting advances in personalized cancer management and emerging challenges.

Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma
Clinical Updatesadjuvant chemotherapycirculating tumor DNA

Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma

By MedXY|Oct 8, 2025

Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.

Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma
Clinical Updatescirculating tumor DNALarge B-Cell Lymphoma

Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma

By MedXY|Oct 7, 2025

Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.

Circulating Tumor DNA as a Biomarker to Guide Timing of CDK4/6 Inhibitor Therapy in Advanced ER+ HER2− Breast Cancer
newsadvanced breast cancerCDK4/6 inhibitors

Circulating Tumor DNA as a Biomarker to Guide Timing of CDK4/6 Inhibitor Therapy in Advanced ER+ HER2− Breast Cancer

By MedXY|Oct 6, 2025

Pretreatment circulating tumor DNA levels can predict which patients with advanced ER-positive, HER2-negative breast cancer benefit more from first-line CDK4/6 inhibitor therapy, supporting personalized treatment strategies.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities